A practical algorithm for managing Alzheimer's disease: what, when, and why?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common form of dementia and its prevalence is increasing. Recent developments in AD management provide improved ways of supporting patients and their caregivers throughout the disease continuum. Managing cardiovascular risk factors, maintaining an active lifestyle (with regular physical, mental and social activity) and following a Mediterranean diet appear to reduce AD risk and may slow cognitive decline. Pharmacologic therapy for AD should be initiated upon diagnosis. All of the currently available cholinesterase inhibitors (ChEIs; donepezil, galantamine, and rivastigmine) are indicated for mild-to-moderate AD. Donepezil (10 and 23 mg/day) and rivastigmine transdermal patch (13.3 mg/24 h) are indicated for moderate-to-severe AD. Memantine, an N-methyl-d-aspartate receptor antagonist, is approved for moderate-to-severe AD. ChEIs have been shown to improve cognitive function, global clinical status and patients' ability to perform activities of daily living. There is also evidence for reduction in emergence of behavioral symptoms with ChEI therapy. Treatment choice (e.g., oral vs. transdermal) should be based on patient or caregiver preference, ease of use, tolerability, and cost. Treatment should be individualized; patients can be switched from one ChEI to another if the initial agent is poorly tolerated or ineffective. Memantine may be introduced in moderate-to-severe disease stages. Clinicians will regularly monitor symptoms and behaviors, manage comorbidities, assess function, educate and help caregivers access information and support, evaluate patients' fitness to drive or own firearms, and provide advice about the need for legal and financial planning. Review of caregiver well-being and prompt referral for support is vital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Obstructive Sleep Apnea as a Risk Factor for Stroke and Death
Yaggi, H. K., Concato, J., Kernan, W. N., Lichtman, J. H., Brass, L. M., & Mohsenin, V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043104 · Cited by 3,004
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“Time to institutionalization and daily living functioning have improved following vitamin E supplementation.(20,21) As with all interventions, the benefit–risk ratio of supplements should be considered.”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 1×
“1);(44,45) biomarkers can be used to define AD as the probable underlying cause of cognitive impairment, but are not strictly necessary for diagnosis.(42,45) The accuracy of diagnosis is enhanced by integration of biomarkers.”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
The Mini-Cog as a screen for dementia: validation in a population-based sample
Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51465.x · Cited by 1,348
Yaffe, K., Laffan, A. M., Harrison, S. L., Redline, S., Spira, A. P., Ensrud, K. E., Ancoli-Israel, S., & Stone, K. L. (2011) · JAMA · doi:10.1001/jama.2011.1115 · Cited by 1,137 · cited 1×
“been reported as a significant risk for dementia in older women, nearly doubling the risk for mild cognitive impairment and dementia over 5 years.(89) It is therefore important for clinicians to evaluate the presence of sleep disordered breathing as another modifiable risk.”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Durga, J., van Boxtel, M. P., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60109-3 · Cited by 758
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378 · cited 1×
“Neuropsychiatric symptoms are a key component of AD, affecting almost all patients over the disease course.(90) Studies suggest that more than 90% of patients with AD show behavioral or neuropsychiatric symptoms, including depression, agitation, anxiety, psychosis, hallucinations, apathy, eating disorders, disinhibiti…”
BackgroundClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365 · cited 1×
“Gastrointestinal (GI) AEs typically arise due to peaks in plasma drug concentrations.(61) Strategies that reduce the”
BackgroundShinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130722 · Cited by 288 · cited 2×
“One trial reported benefits of omega-3 fatty acid and lipoic acid treatment on cognition and ADL performance.(16) However, due to small sample sizes, further studies are required.”
BackgroundNelson, J. C., & Devanand, D. P. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03355.x · Cited by 284
The impact of music therapy on language functioning in dementia
Brotons, M., & Koger, S. M. (2000) · Journal of Music Therapy · doi:10.1093/jmt/37.3.183 · Cited by 237
Galvin, J. E., Roe, C. M., Coats, M. A., & Morris, J. C. (2007) · Archives of Neurology · doi:10.1001/archneur.64.5.725 · Cited by 236
Antidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214
Diet, cognition, and alzheimer’s disease: food for thought
Otaegui-Arrazola, A., Amiano, P., Elbusto, A., Urdaneta, E., & Martínez-Lage, P. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0561-3 · Cited by 214 · cited 1×
“The potential mechanisms by which certain nutrients may protect brain health also remain to be established.(10) Long-term studies on the relationship between physical activity and the incidence of noncommunicable diseases in general is limited.”
BackgroundHealthcare costs and utilization for Medicare beneficiaries with Alzheimer's
Zhao, Y., Kuo, T.-C., Weir, S., Kramer, M. S., & Ash, A. S. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-108 · Cited by 196
Is Music Therapy an Effective Intervention for Dementia? A Meta-Analytic Review of Literature
Koger, S. M., Chapin, K., & Brotons, M. (1999) · Journal of Music Therapy · doi:10.1093/jmt/36.1.2 · Cited by 173
Cited by
New evidence on the management of Lewy body dementia
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30153-x · Cited by 347
Cano, A., Ettcheto, M., Chang, J.-H., Barroso, E., Espina, M., Kühne, B. A., Barenys, M., Auladell, C., Folch, J., Souto, E. B., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.010 · Cited by 337
An explainable machine learning approach for Alzheimer’s disease classification
Alatrany, A. S., Khan, W., Hussain, A., Kolivand, H., & Al-Jumeily, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-51985-w · Cited by 172
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“Later in the course of the disease, the breakdown of physical functions, such as walking, swallowing, and general movement, ultimately leads to death [3].”
Background
Metadata
- Authors
- Cummings, J. L., Isaacson, R. S., Schmitt, F. A., & Velting, D. M.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2015-01-23
- Volume
- 2
- Issue
- 3
- Pages
- 307-323
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2083074012
- Cited by
- 93
- References
- 25
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.